Back to results

Effectiveness of CRD-740 in Heart Failure (CARDINAL-HF)

Primary Purpose

Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction

Status

Active

Phase

Phase 2

Locations

International

Study Type

Interventional

Intervention

CRD-740

Placebo

About this trial

This is an interventional treatment trial for Heart Failure focused on measuring PDE9, Heart Failure, CRD-740, HFpEF, HFrEF

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Males or Females ≥18 years of age, at screening.
Diagnosis of clinical heart failure syndrome, New York Heart Association functional class II - III for at least 6 months prior to screening
For Part A:
- Ejection Fraction ≤40% by echocardiography at screening.
- NT-proBNP level ≥600 pg/ml at screening. Subjects with atrial fibrillation or flutter at screening are required to have an NT-proBNP level of ≥1000 pg/mL at screening.
For Part B:
- For subjects with EF ≤40%:
  - Ejection Fraction ≤40% by echocardiography at screening.
  - NT-proBNP level ≥600 pg/ml at screening. Subjects with atrial fibrillation or flutter at screening are required to have an NT-proBNP level of ≥1000 pg/mL at screening.
- For subjects with EF >40%:
  - EF >40% and left atrial enlargement by echocardiography at screening.
  - NT-proBNP level ≥300 pg/ml at screening. Subjects with atrial fibrillation or flutter at screening are required to have an NT-proBNP level of ≥500 pg/mL at screening.
Stable doses of guideline-directed heart failure therapy for a minimum of 4 weeks prior to screening that has been individually optimized according to standard practice guidelines and no addition of guideline-directed heart failure therapy within 3 months of screening.

Exclusion Criteria:

Documented EF≥60% within 6 months of screening.
Recent HF exacerbation defined by hospitalization or requirement for intravenous diuretics within 60 days of screening.
Subjects with planned interventions (e.g., percutaneous coronary intervention, devices) etc. occurring during their involvement in this study.
Acute coronary syndrome, stroke, transient ischemic attack, cardiac, carotid or other major cardiovascular surgery or carotid angioplasty within 60 days of screening.
Subjects with clinical suspicion of infiltrative cardiomyopathy (e.g., amyloid, sarcoid), hypertrophic cardiomyopathy (obstructive or non-obstructive), or HF secondary to severe valvular disease, active myocarditis, active pericarditis, or clinically significant congenital heart disease.
Prior or planned orthotopic heart transplantation.
Presence of or plan for mechanical circulatory support.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

CRD-740

Placebo

Arm Description

Part A: Participants in Part A randomly assigned to this arm will take CRD-740 twice daily at two ascending dose levels over 12 weeks. Part B: Participants in Part B randomly assigned to this arm will take CRD-740 twice daily at a single dose level over 12 weeks.

Part A: Participants in Part A randomly assigned to this arm will take placebo twice daily at two ascending dose levels over 12 weeks. Part B: Participants in Part B randomly assigned to this arm will take placebo twice daily at a single dose level over 12 weeks.

Outcomes

Primary Outcome Measures

Part A: The change from baseline (Day -1) in plasma cGMP at Week 4.

Part B: The change from baseline (Day 1) in NT-proBNP at Week 12.

Secondary Outcome Measures

Part B: The change from baseline (Day 1) in plasma BNP at Week 12.

Part B: The change from baseline (Day 1) in plasma cGMP at Week 12.

Part B: The change from baseline (Day 1) in the KCCQ-23-CS at Week 12.

Part B: The proportion of subjects with ≥5-point improvement from baseline in the KCCQ-23- CS at Week 12.

Full Information

NCT ID

NCT05409183

First Posted

June 3, 2022

Last Updated

May 8, 2023

Sponsor

Cardurion Pharmaceuticals, Inc.

1. Study Identification

Unique Protocol Identification Number

NCT05409183

Brief Title

Effectiveness of CRD-740 in Heart Failure

Acronym

CARDINAL-HF

Official Title

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Effectiveness of CRD-740 in Subjects With Chronic Heart Failure (CARDINAL-HF)

Study Type

Interventional

2. Study Status

Record Verification Date

May 2023

Overall Recruitment Status

Active, not recruiting

Study Start Date

May 26, 2022 (Actual)

Primary Completion Date

December 2023 (Anticipated)

Study Completion Date

January 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Cardurion Pharmaceuticals, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product

Yes

Studies a U.S. FDA-regulated Device Product

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

This is a two-part study evaluating the effectiveness of CRD-740 in patients with either Heart Failure with Reduced Ejection Fraction (HFrEF) or Heart Failure with Preserved Ejection Fraction (HFpEF) after 12 weeks of treatment. The primary objective in Part A is to assess the effect of CRD-740 compared to placebo in plasma cGMP at Week 4. The primary objective in Part B is to determine whether CRD-740 reduces NT-proBNP compared to placebo at Week 12.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction, Cardiovascular Diseases, Heart Diseases

Keywords

PDE9, Heart Failure, CRD-740, HFpEF, HFrEF

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 2

Interventional Study Model

Parallel Assignment

Masking

ParticipantCare ProviderInvestigatorOutcomes Assessor

Allocation

Randomized

Enrollment

660 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title

CRD-740

Arm Type

Experimental

Arm Description

Arm Title

Placebo

Arm Type

Placebo Comparator

Arm Description

Intervention Type

Drug

Intervention Name(s)

CRD-740

Intervention Description

Tablets administered orally.

Intervention Type

Drug

Intervention Name(s)

Placebo

Intervention Description

Tablets administered orally.

Primary Outcome Measure Information:

Title

Part A: The change from baseline (Day -1) in plasma cGMP at Week 4.

Time Frame

Baseline to Week 4

Title

Part B: The change from baseline (Day 1) in NT-proBNP at Week 12.

Time Frame

Baseline to Week 12

Secondary Outcome Measure Information:

Title

Part B: The change from baseline (Day 1) in plasma BNP at Week 12.

Time Frame

Baseline to Week 12

Title

Part B: The change from baseline (Day 1) in plasma cGMP at Week 12.

Time Frame

Baseline to Week 12

Title

Part B: The change from baseline (Day 1) in the KCCQ-23-CS at Week 12.

Time Frame

Baseline to Week 12

Title

Part B: The proportion of subjects with ≥5-point improvement from baseline in the KCCQ-23- CS at Week 12.

Time Frame

Baseline to Week 12

Other Pre-specified Outcome Measures:

Title

Part A: The change in NT-proBNP from baseline (Day 1) to Week 2, from Week 2 to Week 4, and from Week 2 to Week 12.

Time Frame

Baseline to Week 12

10. Eligibility

Sex

All

Minimum Age & Unit of Time

18 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Males or Females ≥18 years of age, at screening. Diagnosis of clinical heart failure syndrome, New York Heart Association functional class II - III for at least 6 months prior to screening For Part A: Ejection Fraction ≤40% by echocardiography at screening. NT-proBNP level ≥600 pg/ml at screening. Subjects with atrial fibrillation or flutter at screening are required to have an NT-proBNP level of ≥1000 pg/mL at screening. For Part B: For subjects with EF ≤40%: Ejection Fraction ≤40% by echocardiography at screening. NT-proBNP level ≥600 pg/ml at screening. Subjects with atrial fibrillation or flutter at screening are required to have an NT-proBNP level of ≥1000 pg/mL at screening. For subjects with EF >40%: EF >40% and left atrial enlargement by echocardiography at screening. NT-proBNP level ≥300 pg/ml at screening. Subjects with atrial fibrillation or flutter at screening are required to have an NT-proBNP level of ≥500 pg/mL at screening. Stable doses of guideline-directed heart failure therapy for a minimum of 4 weeks prior to screening that has been individually optimized according to standard practice guidelines and no addition of guideline-directed heart failure therapy within 3 months of screening. Exclusion Criteria: Documented EF≥60% within 6 months of screening. Recent HF exacerbation defined by hospitalization or requirement for intravenous diuretics within 60 days of screening. Subjects with planned interventions (e.g., percutaneous coronary intervention, devices) etc. occurring during their involvement in this study. Acute coronary syndrome, stroke, transient ischemic attack, cardiac, carotid or other major cardiovascular surgery or carotid angioplasty within 60 days of screening. Subjects with clinical suspicion of infiltrative cardiomyopathy (e.g., amyloid, sarcoid), hypertrophic cardiomyopathy (obstructive or non-obstructive), or HF secondary to severe valvular disease, active myocarditis, active pericarditis, or clinically significant congenital heart disease. Prior or planned orthotopic heart transplantation. Presence of or plan for mechanical circulatory support. Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Elizabeth Moore, DNP, CPNP-AC, CPN

Organizational Affiliation

Senior Director, Clinical Research

Official's Role

Study Director

Facility Information:

Facility Name

Cardurion Investigative Site

City

Alexander City

State/Province

Alabama

ZIP/Postal Code

35010

Country

United States

Facility Name

Cardurion Investigative Site

City

Birmingham

State/Province

Alabama

ZIP/Postal Code

35211

Country

United States

Facility Name

Cardurion Investigative Site

City

Fairhope

State/Province

Alabama

ZIP/Postal Code

36532

Country

United States

Facility Name

Cardurion Investigative Site

City

Torrance

State/Province

California

ZIP/Postal Code

90502

Country

United States

Facility Name

Cardurion Investigative Site

City

West Hills

State/Province

California

ZIP/Postal Code

91307

Country

United States

Facility Name

Cardurion Investigative Site

City

Washington

State/Province

District of Columbia

ZIP/Postal Code

20010

Country

United States

Facility Name

Cardurion Investigative Site

City

Hialeah

State/Province

Florida

ZIP/Postal Code

33016

Country

United States

Facility Name

Cardurion Investigative Site

City

Miami

State/Province

Florida

ZIP/Postal Code

33133

Country

United States

Facility Name

Cardurion Investigative Site

City

Miami

State/Province

Florida

ZIP/Postal Code

33169

Country

United States

Facility Name

Cardurion Investigative Site

City

Naples

State/Province

Florida

ZIP/Postal Code

34102

Country

United States

Facility Name

Cardurion Investigative Site

City

Naples

State/Province

Florida

ZIP/Postal Code

34109

Country

United States

Facility Name

Cardurion Investigative Site

City

Tampa

State/Province

Florida

ZIP/Postal Code

33612

Country

United States

Facility Name

Cardurion Investigative Site

City

Zephyrhills

State/Province

Florida

ZIP/Postal Code

33541

Country

United States

Facility Name

Cardurion Investigative Site

City

Atlanta

State/Province

Georgia

ZIP/Postal Code

30303

Country

United States

Facility Name

Cardurion Investigative Site

City

Eatonton

State/Province

Georgia

ZIP/Postal Code

31024

Country

United States

Facility Name

Cardurion Investigative Site

City

Hazel Crest

State/Province

Illinois

ZIP/Postal Code

60429

Country

United States

Facility Name

Cardurion Investigative Site

City

Winfield

State/Province

Illinois

ZIP/Postal Code

60190

Country

United States

Facility Name

Cardurion Investigative Site

City

Wichita

State/Province

Kansas

ZIP/Postal Code

67207

Country

United States

Facility Name

Cardurion Investigative Site

City

Alexandria

State/Province

Louisiana

ZIP/Postal Code

71301

Country

United States

Facility Name

Cardurion Investigative Site

City

Bossier City

State/Province

Louisiana

ZIP/Postal Code

71111

Country

United States

Facility Name

Cardurion Investigative Site

City

Detroit

State/Province

Michigan

ZIP/Postal Code

48202

Country

United States

Facility Name

Cardurion Investigative Site

City

Minneapolis

State/Province

Minnesota

ZIP/Postal Code

55417

Country

United States

Facility Name

Cardurion Investigative Site

City

Jackson

State/Province

Mississippi

ZIP/Postal Code

39216

Country

United States

Facility Name

Cardurion Investigative Site

City

New York

State/Province

New York

ZIP/Postal Code

10029

Country

United States

Facility Name

Cardurion Investigative Site

City

Chapel Hill

State/Province

North Carolina

ZIP/Postal Code

27599

Country

United States

Facility Name

Cardurion Investigative Site

City

Greensboro

State/Province

North Carolina

ZIP/Postal Code

27405

Country

United States

Facility Name

Cardurion Investigative Site

City

Cleveland

State/Province

Ohio

ZIP/Postal Code

44195

Country

United States

Facility Name

Cardurion Investigative Site

City

Portland

State/Province

Oregon

ZIP/Postal Code

97239

Country

United States

Facility Name

Cardurion Investigative Site

City

Pittsburgh

State/Province

Pennsylvania

ZIP/Postal Code

15212

Country

United States

Facility Name

Cardurion Investigative Site

City

Sioux Falls

State/Province

South Dakota

ZIP/Postal Code

57105

Country

United States

Facility Name

Cardurion Investigative Site

City

Germantown

State/Province

Tennessee

ZIP/Postal Code

38138

Country

United States

Facility Name

Cardurion Investigative Site

City

Tullahoma

State/Province

Tennessee

ZIP/Postal Code

37388

Country

United States

Facility Name

Cardurion Investigative Site

City

Allen

State/Province

Texas

ZIP/Postal Code

75013

Country

United States

Facility Name

Cardurion Investigative Site

City

Dallas

State/Province

Texas

ZIP/Postal Code

75390

Country

United States

Facility Name

Cardurion Investigative Site

City

Norfolk

State/Province

Virginia

ZIP/Postal Code

23510

Country

United States

Facility Name

Cardurion Investigative Site

City

Madison

State/Province

Wisconsin

ZIP/Postal Code

53792

Country

United States

Facility Name

Cardurion Investigative Site

City

Blagoevgrad

ZIP/Postal Code

2700

Country

Bulgaria

Facility Name

Cardurion Investigative Site

City

Haskovo

ZIP/Postal Code

6300

Country

Bulgaria

Facility Name

Cardurion Investigative Site

City

Haskovo

ZIP/Postal Code

6304

Country

Bulgaria

Facility Name

Cardurion Investigative Site

City

Kyustendil

ZIP/Postal Code

2500

Country

Bulgaria

Facility Name

Cardurion Investigative Site

City

Pleven

ZIP/Postal Code

5806

Country

Bulgaria

Facility Name

Cardurion Investigative Site

City

Plovdiv

ZIP/Postal Code

4002

Country

Bulgaria

Facility Name

Cardurion Investigative Site

City

Plovdiv

ZIP/Postal Code

4003

Country

Bulgaria

Facility Name

Cardurion Investigative Site

City

Smolyan

ZIP/Postal Code

4700

Country

Bulgaria

Facility Name

Cardurion Investigative Site

City

Sofia

ZIP/Postal Code

1202

Country

Bulgaria

Facility Name

Cardurion Investigative Site

City

Sofia

ZIP/Postal Code

1407

Country

Bulgaria

Facility Name

Cardurion Investigative Site

City

Sofia

ZIP/Postal Code

1510

Country

Bulgaria

Facility Name

Cardurion Investigative Site

City

Sofia

ZIP/Postal Code

1527

Country

Bulgaria

Facility Name

Cardurion Investigative Site

City

Sofia

ZIP/Postal Code

1606

Country

Bulgaria

Facility Name

Cardurion Investigative Site

City

Sofia

ZIP/Postal Code

1709

Country

Bulgaria

Facility Name

Cardurion Investigative Site

City

Edmonton

State/Province

Alberta

ZIP/Postal Code

T6G 2H7

Country

Canada

Facility Name

Cardurion Investigative Site

City

Vancouver

State/Province

British Columbia

ZIP/Postal Code

V5Z 1M9

Country

Canada

Facility Name

Cardurion Investigative Site

City

Victoria

State/Province

British Columbia

ZIP/Postal Code

V8R 1B2

Country

Canada

Facility Name

Cardurion Investigative Site

City

Winnipeg

State/Province

Manitoba

ZIP/Postal Code

R2H 2A6

Country

Canada

Facility Name

Cardurion Investigative Site

City

Saint John's

State/Province

Newfoundland and Labrador

ZIP/Postal Code

A1B 3V6

Country

Canada

Facility Name

Cardurion Investigative Site

City

Halifax

State/Province

Nova Scotia

ZIP/Postal Code

B3H 3A7

Country

Canada

Facility Name

Cardurion Investigative Site

City

Brampton

State/Province

Ontario

ZIP/Postal Code

L6Z 4N5

Country

Canada

Facility Name

Cardurion Investigative Site

City

Oshawa

State/Province

Ontario

ZIP/Postal Code

L1J 2K1

Country

Canada

Facility Name

Cardurion Investigative Site

City

Montréal

State/Province

Quebec

ZIP/Postal Code

H1T 1C8

Country

Canada

Facility Name

Cardurion Investigative Site

City

Montréal

State/Province

Quebec

ZIP/Postal Code

H3G 1A4

Country

Canada

Facility Name

Cardurion Investigative Site

City

Québec

State/Province

Quebec

ZIP/Postal Code

G1V 4G5

Country

Canada

Facility Name

Cardurion Investigative Site

City

Sherbrooke

State/Province

Quebec

ZIP/Postal Code

J1G 2E8

Country

Canada

Facility Name

Cardurion Investigative Site

City

Brandýs Nad Labem-Stará Boleslav

ZIP/Postal Code

25001

Country

Czechia

Facility Name

Cardurion Investigative Site

City

Prague

ZIP/Postal Code

12800

Country

Czechia

Facility Name

Cardurion Investigative Site

City

Prague

ZIP/Postal Code

15030

Country

Czechia

Facility Name

Cardurion Investigative Site

City

Příbram

ZIP/Postal Code

26101

Country

Czechia

Facility Name

Cardurion Investigative Site

City

Balatonfüred

ZIP/Postal Code

8230

Country

Hungary

Facility Name

Cardurion Investigative Site

City

Budapest

ZIP/Postal Code

1051

Country

Hungary

Facility Name

Cardurion Investigative Site

City

Budapest

ZIP/Postal Code

1122

Country

Hungary

Facility Name

Cardurion Investigative Site

City

Budapest

ZIP/Postal Code

1134

Country

Hungary

Facility Name

Cardurion Investigative Site

City

Debrecen

ZIP/Postal Code

4032

Country

Hungary

Facility Name

Cardurion Investigative Site

City

Gyöngyös

ZIP/Postal Code

3200

Country

Hungary

Facility Name

Cardurion Investigative Site

City

Kaposvár

ZIP/Postal Code

7400

Country

Hungary

Facility Name

Cardurion Investigative Site

City

Kistarcsa

ZIP/Postal Code

2143

Country

Hungary

Facility Name

Cardurion Investigative Site

City

Nyíregyháza

ZIP/Postal Code

4400

Country

Hungary

Facility Name

Cardurion Investigative Site

City

Zalaegerszeg

ZIP/Postal Code

8900

Country

Hungary

Facility Name

Cardurion Investigative Site

City

Ashkelon

ZIP/Postal Code

7830604

Country

Israel

Facility Name

Cardurion Investigative Site

City

Be'er Ya'aqov

ZIP/Postal Code

70300

Country

Israel

Facility Name

Cardurion Investigative Site

City

Hadera

ZIP/Postal Code

38100

Country

Israel

Facility Name

Cardurion Investigative Site

City

Haifa

ZIP/Postal Code

31096

Country

Israel

Facility Name

Cardurion Investigative Site

City

Haifa

ZIP/Postal Code

31999

Country

Israel

Facility Name

Cardurion Investigative Site

City

Jerusalem

ZIP/Postal Code

9000

Country

Israel

Facility Name

Cardurion Investigative Site

City

Kfar Sava

ZIP/Postal Code

4428164

Country

Israel

Facility Name

Cardurion Investigative Site

City

Nahariya

ZIP/Postal Code

2210001

Country

Israel

Facility Name

Cardurion Investigative Site

City

Petah Tikva

ZIP/Postal Code

49100

Country

Israel

Facility Name

Cardurion Investigative Site

City

Reẖovot

ZIP/Postal Code

76100

Country

Israel

Facility Name

Cardurion Investigative Site

City

Tiberias

ZIP/Postal Code

15208

Country

Israel

Facility Name

Cardurion Investigative Site

City

Pozzilli

State/Province

Isernia

ZIP/Postal Code

86077

Country

Italy

Facility Name

Cardurion Investigative Site

City

Rozzano

State/Province

Milan

ZIP/Postal Code

20089

Country

Italy

Facility Name

Cardurion Investigative Site

City

Bergamo

ZIP/Postal Code

24127

Country

Italy

Facility Name

Cardurion Investigative Site

City

Milan

ZIP/Postal Code

20138

Country

Italy

Facility Name

Cardurion Investigative Site

City

Palermo

ZIP/Postal Code

90127

Country

Italy

Facility Name

Cardurion Investigative Site

City

Pavia

ZIP/Postal Code

27100

Country

Italy

Facility Name

Cardurion Investigative Site

City

Sassari

ZIP/Postal Code

07100

Country

Italy

Facility Name

Cardurion Investigative Site

City

Wrocław

State/Province

Dolnoslaskie

ZIP/Postal Code

50-556

Country

Poland

Facility Name

Cardurion Investigative Site

City

Chrzanów

State/Province

Malopolskie

ZIP/Postal Code

32-500

Country

Poland

Facility Name

Cardurion Investigative Site

City

Krakow

State/Province

Malopolskie

ZIP/Postal Code

30-076

Country

Poland

Facility Name

Cardurion Investigative Site

City

Grodzisk Mazowiecki

State/Province

Mazowieckie

ZIP/Postal Code

30-076

Country

Poland

Facility Name

Cardurion Investigative Site

City

Tychy

State/Province

Silesia

ZIP/Postal Code

43-100

Country

Poland

Facility Name

Cardurion Investigative Site

City

Jasło

State/Province

Woj. Podkarpackie

ZIP/Postal Code

38-200

Country

Poland

Facility Name

Cardurion Investigative Site

City

Kraków

ZIP/Postal Code

30-363

Country

Poland

Facility Name

Cardurion Investigative Site

City

Lublin

ZIP/Postal Code

20078

Country

Poland

Facility Name

Cardurion Investigative Site

City

Poznań

ZIP/Postal Code

61-144

Country

Poland

Facility Name

Cardurion Investigative Site

City

Wrocław

ZIP/Postal Code

50-981

Country

Poland

Facility Name

Cardurion Investigative Site

City

Wrocław

ZIP/Postal Code

51-162

Country

Poland

Facility Name

Cardurion Investigative Site

City

Łódź

ZIP/Postal Code

92-213

Country

Poland

Facility Name

Cardurion Investigative Site

City

Łódź

ZIP/Postal Code

93-513

Country

Poland

Facility Name

Cardurion Investigative Site

City

Brezno

State/Province

Banskobystricky

ZIP/Postal Code

97701

Country

Slovakia

Facility Name

Cardurion Investigative Site

City

Lučenec

State/Province

Banskobystricky

ZIP/Postal Code

98401

Country

Slovakia

Facility Name

Cardurion Investigative Site

City

Lučenec

State/Province

Banskobystricky

ZIP/Postal Code

98439

Country

Slovakia

Facility Name

Cardurion Investigative Site

City

Trebišov

State/Province

Kosice

ZIP/Postal Code

07501

Country

Slovakia

Facility Name

Cardurion Investigative Site

City

Prešov

State/Province

Presovsky

ZIP/Postal Code

08001

Country

Slovakia

Facility Name

Cardurion Investigative Site

City

Svidník

State/Province

Presovsky

ZIP/Postal Code

08901

Country

Slovakia

Facility Name

Cardurion Investigative Site

City

Bardejov

ZIP/Postal Code

08501

Country

Slovakia

Facility Name

Cardurion Investigative Site

City

High Wycombe

State/Province

Buckinghamshire

ZIP/Postal Code

HP11 2TT

Country

United Kingdom

Facility Name

Cardurion Investigative Site

City

Airdrie

State/Province

Lanarkshire

ZIP/Postal Code

ML6 8LL

Country

United Kingdom

Facility Name

Cardurion Investigative Site

City

Isleworth

State/Province

Middlesex

ZIP/Postal Code

TW7 6AF

Country

United Kingdom

Facility Name

Cardurion Investigative Site

City

Clydebank

ZIP/Postal Code

G81 4DY

Country

United Kingdom

Facility Name

Cardurion Investigative Site

City

Dundee

ZIP/Postal Code

DD1 4HN

Country

United Kingdom

Facility Name

Cardurion Investigative Site

City

Glasgow

ZIP/Postal Code

G4 0SF

Country

United Kingdom

Facility Name

Cardurion Investigative Site

City

Harrow

ZIP/Postal Code

HA1 3UJ

Country

United Kingdom

Facility Name

Cardurion Investigative Site

City

Newcastle Upon Tyne

ZIP/Postal Code

NE1 4LP

Country

United Kingdom

Facility Name

Cardurion Investigative Site

City

Stockton-on-Tees

ZIP/Postal Code

TS19 8PE

Country

United Kingdom

12. IPD Sharing Statement

Plan to Share IPD

Learn more about this trial

Effectiveness of CRD-740 in Heart Failure

We'll reach out to this number within 24 hrs

Effectiveness of CRD-740 in Heart Failure (CARDINAL-HF)

Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction

About this trial

Eligibility Criteria

Sites / Locations

Arms of the Study

Arm 1

Arm 2

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

1. Study Identification

2. Study Status

3. Sponsor/Collaborators

4. Oversight

5. Study Description

6. Conditions and Keywords

7. Study Design

8. Arms, Groups, and Interventions

10. Eligibility

12. IPD Sharing Statement

Learn more about this trial